Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Short Interest Update

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) saw a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 3,260,000 shares, a decline of 18.9% from the November 30th total of 4,020,000 shares. Based on an average daily volume of 311,200 shares, the days-to-cover ratio is currently 10.5 days.

Kiniksa Pharmaceuticals Trading Down 2.0 %

KNSA traded down $0.41 on Monday, hitting $19.60. 863,378 shares of the company were exchanged, compared to its average volume of 399,292. The firm has a 50-day moving average price of $22.13 and a two-hundred day moving average price of $23.18. Kiniksa Pharmaceuticals has a twelve month low of $16.56 and a twelve month high of $28.15. The company has a market cap of $1.42 billion, a price-to-earnings ratio of -139.99 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The company had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business’s quarterly revenue was up 67.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.20) earnings per share. Equities analysts expect that Kiniksa Pharmaceuticals will post -0.55 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on KNSA shares. Jefferies Financial Group assumed coverage on Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective for the company. Evercore ISI increased their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $36.60.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,000 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total transaction of $456,790.00. Following the completion of the transaction, the chief operating officer now owns 109,975 shares of the company’s stock, valued at $2,955,028.25. This trade represents a 13.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total transaction of $192,385.05. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares in the company, valued at $492,449.10. This trade represents a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,092 shares of company stock worth $673,039 in the last ninety days. 54.57% of the stock is owned by insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of large investors have recently modified their holdings of the company. JPMorgan Chase & Co. purchased a new position in Kiniksa Pharmaceuticals in the third quarter valued at $4,997,000. Franklin Resources Inc. boosted its position in shares of Kiniksa Pharmaceuticals by 1.7% during the 3rd quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock worth $1,798,000 after acquiring an additional 1,100 shares in the last quarter. XTX Topco Ltd increased its holdings in shares of Kiniksa Pharmaceuticals by 62.2% in the 3rd quarter. XTX Topco Ltd now owns 27,302 shares of the company’s stock valued at $682,000 after acquiring an additional 10,474 shares during the last quarter. Castleark Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth about $4,178,000. Finally, Jane Street Group LLC increased its stake in Kiniksa Pharmaceuticals by 1,064.4% in the third quarter. Jane Street Group LLC now owns 345,092 shares of the company’s stock valued at $8,624,000 after purchasing an additional 315,456 shares during the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.